Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Exclusion Criteria

• •1. Known to be allergic to the received therapeutic drugs or excipients;
• •2. Baseline LVEF\<50% (measured by echocardiography or MUGA);
• •3. Previously received treatment with anti-HER2 ADC drugs;
• •4. Individuals who have undergone systemic immunotherapy, biologic therapy, or participated in any clinical drug trials within the past 2 weeks;
• •5. Those who have undergone surgery within 3 weeks before the start of the experimental treatment and have not fully recovered;
• •6. Patients with uncontrolled central nervous system (CNS) metastases or epilepsy requiring medication treatment;
• •7. Serious systemic diseases. Such as infected or uncontrolled diabetes;
• •8. Suffering from other malignant tumors within 5 years, except for non melanoma skin cancer and cervical carcinoma in situ;
• •9. Clinically symptomatic active coronary heart disease, cardiomyopathy, or congestive heart failure, NYHA III-IV; uncontrolled hypertension (systolic blood pressure\>180 mmHg or diastolic blood pressure\>100 mmHg), clinically symptomatic heart valve disease, or high-risk arrhythmia;
• •10. Patients receiving long-term or high-dose corticosteroid treatment (inhaled steroids or short-term oral steroids are allowed to resist vomiting or promote appetite)
• •11. Individuals without legal capacity, those whose medical or ethical reasons affect the continuation of research;
• •12. Pregnant and lactating female patients, or those who wish to become pregnant during treatment;
• •13. Uncontrolled pleural and peritoneal effusion;
• •14. There is a persistent infection of\>level 2 (CTC-AE 4.0); Wounds, ulcers, or fractures that cannot heal, or patients with a history of organ transplantation;
• •15. There are unresolved toxicity levels\>1 caused by any previous treatment/procedure (CTC-AE 4.0, excluding hair loss, anemia, and hypothyroidism);
• •16. After comprehensive assessment of the patient's condition by the researchers, it is deemed that they are not suitable to participate in this study;
• •17. Simultaneously participating in another clinical study.